All Blogs

Jul 16, 2015

DelveInsight, the leading market research and consulting company has added Oncology based Reports to its portfolio. With this launch DelveInsight now has 100+ Oncology based Reports. In addition to this, our research expertise provides our clients with up to date information of market till the date on which order is...

Jul 07, 2015

DelveInsight expertise over 400+ Indication Active Pharmaceutical Ingredient (API) Reports DelveInsight, leading Market Research and Business Consulting firm has an expertise in providing business solutions to Pharma and biotech companies. DelveInsight has 400+ Indication API reports on wide range of therapeutic ...

Jun 30, 2015

“We designed CAR T cells to overcome a number of problems in getting T cells to attack Cancer”-says Eshhar, after the development of first CAR-T cells (1989). CAR-T Technologies and History of Innovations Ever so often in the history of immunotherapy, there comes a breakthrough that takes cancer research ...

Jun 17, 2015

In the field of oncology, no other approach is as attentive as Immunotherapy. Renewed interest in immunotherapy has been driven by Chimeric Antigen Receptor (CAR) T-cell therapy. This emerging approach is (CAR) T-cell technology which is showing great promise in immunotherapy. There are 35+ products in pipeline and...

Jun 13, 2015

DelveInsight is Hiring!!! Looking for Passionate Candidates Mail your updated Resume to careers@delveinsight.com JOB DESCRIPTION Profile Offered: Analyst (2-4 years Experienced) Education: M. Pharma/M.tech Biotech/MBA Biotech/B.Tech/ Roles and Responsibilities: Excellent editing, verbal and written ...

Jun 03, 2015

Drugs with better pharmacodymics and improved treatment algorithm with antiproliferative and anti-inflammatory treatments are needed! Pulmonary arterial hypertension (PAH) is rare lung disorder affecting pulmonary arteries. It is a fatal disease associated with the vasoconstriction and vascular remodeling that i...

May 04, 2015

The current cancer therapies and drug design strategies developed are more precisely aimed at targeting the cancer cells. Primary challenge in selectively targeting cancer cells is to differentiate between the cancer cells and the normal cells. One such difference is enzyme telomerase activity which has been an exc...

Apr 21, 2015

VTE therapeutics & Atrial Fibrillation market was worth USD 4 billion in 2014 and USD 7.86 billion respectively. The VTE therapeutic market is expected to reach USD 5.5 billion by 2018 with a Compound Annual Growth Rate (CAGR) of 8.29% and Atrial Fibrillation market will reach on its peak value USD 13.28 billi...

Apr 17, 2015

Big Pharma Guiding the Stem Cells Future Stem cells (SCs) have been an excitement area of medical research since 1800s. In the mid 1800s it was discovered that cells were basically the building blocks of life and that some cells had the ability to produce other cells and in 1900 scientists had discovered that some...

Apr 13, 2015

PD-1and PDL-1 are the next targeted agents in Oncology. These therapies have the enormous potential to treat cancer and have an excellent response in the increasing number of patients. Many experts say that out of all of the therapies, PD-1/PD-L1 inhibitors look to be the most promising in treating cancer. DelveIns...